News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,537 Results
Type
Article (15293)
Company Profile (282)
Press Release (259962)
Section
Business (81040)
Career Advice (165)
Deals (13455)
Drug Delivery (37)
Drug Development (51586)
Employer Resources (31)
FDA (6006)
Job Trends (5305)
News (147645)
Policy (10305)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1007)
Accelerated approval (3)
Adcomms (13)
Allergies (50)
Alliances (22378)
ALS (64)
Alzheimer's disease (892)
Antibody-drug conjugate (ADC) (88)
Approvals (6022)
Artificial intelligence (121)
Autoimmune disease (13)
Automation (6)
Bankruptcy (106)
Best Places to Work (4726)
BIOSECURE Act (5)
Biosimilars (41)
Biotechnology (232)
Bladder cancer (47)
Brain cancer (20)
Breast cancer (151)
Cancer (1366)
Cardiovascular disease (114)
Career advice (143)
Career pathing (2)
CAR-T (108)
Cell therapy (311)
Cervical cancer (8)
Clinical research (41824)
Collaboration (515)
Compensation (226)
Complete response letters (13)
COVID-19 (1086)
CRISPR (38)
C-suite (147)
Cystic fibrosis (76)
Data (1415)
Denatured (11)
Depression (29)
Diabetes (128)
Diagnostics (1873)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (80)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (30142)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (49187)
Executive appointments (411)
FDA (6654)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (473)
Gene editing (91)
Generative AI (10)
Gene therapy (234)
GLP-1 (365)
Government (1113)
Grass and pollen (2)
Guidances (18)
Healthcare (6860)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (83)
Indications (18)
Infectious disease (1149)
Inflammatory bowel disease (112)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (19)
IPO (7344)
IRA (11)
Job creations (877)
Job search strategy (137)
Kidney cancer (6)
Labor market (4)
Layoffs (204)
Leadership (2)
Legal (1415)
Liver cancer (35)
Lung cancer (194)
Lymphoma (88)
Machine learning (2)
Management (7)
Manufacturing (117)
MASH (50)
Medical device (2718)
Medtech (2719)
Mergers & acquisitions (6410)
Metabolic disorders (373)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (66)
Neuropsychiatric disorders (23)
Neuroscience (1274)
NextGen: Class of 2025 (2060)
Non-profit (913)
Northern California (1591)
Now hiring (21)
Obesity (190)
Opinion (104)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (51)
Parkinson's disease (110)
Partnered (8)
Patents (114)
Patient recruitment (68)
Peanut (35)
People (25789)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14696)
Phase II (19464)
Phase III (12301)
Pipeline (749)
Podcasts (47)
Policy (38)
Postmarket research (904)
Preclinical (6174)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (282)
Real estate (1442)
Recruiting (12)
Regulatory (8810)
Reports (16)
Research institute (1007)
Resumes & cover letters (20)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (92)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1418)
Special edition (11)
Spinal muscular atrophy (118)
Sponsored (11)
Startups (1995)
State (1)
Stomach cancer (4)
Supply chain (18)
Tariffs (3)
The Weekly (35)
United States (12456)
Vaccines (211)
Venture capitalists (28)
Webinars (7)
Weight loss (107)
Women's health (15)
Worklife (2)
Date
Today (69)
Last 7 days (461)
Last 30 days (1666)
Last 365 days (20337)
2025 (5015)
2024 (20930)
2023 (22868)
2022 (27487)
2021 (28529)
2020 (24034)
2019 (16761)
2018 (12132)
2017 (14226)
2016 (12351)
2015 (14863)
2014 (10791)
2013 (7841)
2012 (7891)
2011 (7977)
2010 (7776)
Location
Africa (162)
Alabama (38)
Alaska (2)
Arizona (58)
Arkansas (5)
Asia (17700)
Australia (3112)
California (3619)
Canada (1073)
China (327)
Colorado (141)
Connecticut (147)
Delaware (89)
Europe (38548)
Florida (429)
Georgia (110)
Idaho (17)
Illinois (220)
India (10)
Indiana (94)
Iowa (1)
Japan (72)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (448)
Massachusetts (2853)
Michigan (70)
Minnesota (139)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (16)
New Hampshire (14)
New Jersey (899)
New Mexico (12)
New York (972)
North Carolina (528)
North Dakota (4)
Northern California (1591)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (689)
Puerto Rico (3)
Rhode Island (15)
South America (231)
South Carolina (6)
Southern California (1418)
Tennessee (27)
Texas (420)
Utah (66)
Virginia (71)
Washington D.C. (28)
Washington State (330)
Wisconsin (20)
275,537 Results for "marker therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
April 1, 2025
·
1 min read
Press Releases
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
April 1, 2025
·
11 min read
Press Releases
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 26, 2025
·
3 min read
Press Releases
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
December 20, 2024
·
8 min read
Press Releases
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 26, 2024
·
3 min read
Press Releases
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
December 10, 2024
·
3 min read
Lone Star Bio
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.
March 22, 2024
·
3 min read
Business
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.
May 15, 2024
·
12 min read
Press Releases
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024
·
10 min read
Business
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported recent corporate developments and financial results for the year ended December 31, 2023.
March 25, 2024
·
14 min read
1 of 27,554
Next
